Athira Pharma (NASDAQ:ATHA) Cut to “Market Perform” at JMP Securities

JMP Securities cut shares of Athira Pharma (NASDAQ:ATHA) from an outperform rating to a market perform rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports.

Separately, Rodman & Renshaw began coverage on Athira Pharma in a research report on Monday, August 19th. They issued a buy rating and a $22.00 price objective on the stock.

Athira Pharma Stock Down 3.6 %

Shares of Athira Pharma stock opened at $0.54 on Wednesday. The stock’s 50-day simple moving average is $2.97 and its 200-day simple moving average is $2.75. Athira Pharma has a 52 week low of $0.52 and a 52 week high of $4.30. The company has a market capitalization of $20.75 million, a price-to-earnings ratio of -0.18 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.05. On average, equities analysts expect that Athira Pharma will post -2.56 earnings per share for the current year.

Insider Transactions at Athira Pharma

In other news, Director Kelly A. Romano bought 15,000 shares of Athira Pharma stock in a transaction dated Friday, June 21st. The shares were purchased at an average cost of $2.26 per share, with a total value of $33,900.00. Following the completion of the acquisition, the director now owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Kelly A. Romano acquired 15,000 shares of Athira Pharma stock in a transaction on Friday, June 21st. The shares were bought at an average cost of $2.26 per share, with a total value of $33,900.00. Following the completion of the purchase, the director now directly owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kelly A. Romano acquired 27,400 shares of Athira Pharma stock in a transaction on Monday, June 24th. The shares were bought at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the purchase, the director now directly owns 80,715 shares of the company’s stock, valued at $195,330.30. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 8,829 shares of company stock valued at $5,033. 19.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Athira Pharma

Several large investors have recently added to or reduced their stakes in ATHA. Private Advisor Group LLC purchased a new position in shares of Athira Pharma during the fourth quarter valued at approximately $32,000. Rothschild Investment LLC purchased a new position in shares of Athira Pharma during the second quarter valued at approximately $34,000. Mirador Capital Partners LP purchased a new position in shares of Athira Pharma during the first quarter valued at approximately $57,000. XTX Topco Ltd purchased a new position in shares of Athira Pharma during the second quarter valued at approximately $60,000. Finally, Invst LLC purchased a new position in shares of Athira Pharma during the second quarter valued at approximately $68,000. 57.12% of the stock is owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.